Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIANCA phase II trial of tisagenlecleucel in pediatric relapsed or refractory mature B-cell NHL
NL-OMON49158Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in mature B-cell lymphoma and Burkitt leukemia, sponsored by Novartis. Primary endpoint: Overall response rate. Started Dec 2019; status: active, not recruiting.
02
Drugs
tisagenlecleucel
03
Conditions
mature B-cell lymphomaBurkitt leukemia
Beyond the preview
Go deeper on NL-OMON49158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49158.